<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/category/news/science-news/cancer-science-news/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 18 Jul 2026 07:54:54 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Cancer &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel</title>
		<link>https://bioengineer.org/randomized-phase-ii-trial-tests-nivolumab-then-nivolumab-ipilimumab-or-docetaxel/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 18 Jul 2026 07:54:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/randomized-phase-ii-trial-tests-nivolumab-then-nivolumab-ipilimumab-or-docetaxel/</guid>

					<description><![CDATA[A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with recurrent or metastatic squamous cell carcinoma of the head and neck. Reported in British Journal of Cancer, the study evaluates a treatment strategy that begins with nivolumab and then selects the next step based on [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">366326</post-id>	</item>
		<item>
		<title>KPNA2 overexpression worsens T4 colorectal cancer prognosis by nuclear c-Myc suppression of p21</title>
		<link>https://bioengineer.org/kpna2-overexpression-worsens-t4-colorectal-cancer-prognosis-by-nuclear-c-myc-suppression-of-p21/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 21:36:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/kpna2-overexpression-worsens-t4-colorectal-cancer-prognosis-by-nuclear-c-myc-suppression-of-p21/</guid>

					<description><![CDATA[Advanced colorectal cancer remains one of oncology’s toughest challenges, especially in pathological T4 (pT4) disease where outcomes are often grim. A new study now points to a molecular driver that could help explain why some pT4 tumors progress aggressively and may even offer a prognostic handle. The work centers on Karyopherin alpha 2 (KPNA2), a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">366248</post-id>	</item>
		<item>
		<title>Blood DNA test better selects patients for prostate cancer radiopharmaceutical therapy</title>
		<link>https://bioengineer.org/blood-dna-test-better-selects-patients-for-prostate-cancer-radiopharmaceutical-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 20:18:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/blood-dna-test-better-selects-patients-for-prostate-cancer-radiopharmaceutical-therapy/</guid>

					<description><![CDATA[A simple blood test may soon help clinicians manage metastatic castration-resistant prostate cancer (mCRPC) more precisely, according to a study appearing in the July issue of The Journal of Nuclear Medicine. Researchers report that circulating tumor DNA (ctDNA) profiling can flag which patients are most likely to benefit from radium-223 (^223Ra) radiopharmaceutical therapy, and can [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">366211</post-id>	</item>
		<item>
		<title>IRP1/ARID3A complex identified as a new epigenetic driver of pancreatic cancer chemoresistance</title>
		<link>https://bioengineer.org/irp1-arid3a-complex-identified-as-a-new-epigenetic-driver-of-pancreatic-cancer-chemoresistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 17:31:02 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/irp1-arid3a-complex-identified-as-a-new-epigenetic-driver-of-pancreatic-cancer-chemoresistance/</guid>

					<description><![CDATA[Pancreatic cancer remains among the deadliest malignancies, in part because tumors often withstand chemotherapy and later acquire resistance. In recent years, ferroptosis—an iron-dependent, lipid-peroxidation-driven cell death—has emerged as a potential strategy to bypass conventional resistance mechanisms. Yet many pancreatic cancers still evade ferroptosis, leaving a crucial gap in understanding the molecular circuitry behind treatment failure. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">366160</post-id>	</item>
		<item>
		<title>Revisiting Link Between Vegetarian Diet and Cancer Risk</title>
		<link>https://bioengineer.org/revisiting-link-between-vegetarian-diet-and-cancer-risk/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 16:24:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revisiting-link-between-vegetarian-diet-and-cancer-risk/</guid>

					<description><![CDATA[A new analysis reopens one of nutrition science’s most debated questions: whether vegetarian diets change cancer risk. In a commentary published in British Journal of Cancer, researchers Ma, Guo, and Shi argue that the relationship is more complicated than simple “vegetarian equals lower risk” narratives. Their work emphasizes that prior conclusions have often been shaped [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">366140</post-id>	</item>
		<item>
		<title>Chinese hospital study finds smarter brain surgery boosts patient survival</title>
		<link>https://bioengineer.org/chinese-hospital-study-finds-smarter-brain-surgery-boosts-patient-survival/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 16:06:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/chinese-hospital-study-finds-smarter-brain-surgery-boosts-patient-survival/</guid>

					<description><![CDATA[Brain tumor surgery often hinges on a high-stakes trade-off: maximizing resection while protecting neurological function. Lesions near the corpus callosum are among the hardest cases because this deep midline structure serves as the brain’s major communication highway between hemispheres and sits close to critical fiber tracts. For patients with IDH-mutant low-grade corpus callosum glioma (ccLGG), [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">366133</post-id>	</item>
		<item>
		<title>ZBP1 Links Genomic Stress to Tumor Immunity, New Study Finds</title>
		<link>https://bioengineer.org/zbp1-links-genomic-stress-to-tumor-immunity-new-study-finds/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 02:35:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/zbp1-links-genomic-stress-to-tumor-immunity-new-study-finds/</guid>

					<description><![CDATA[A new open-access Review in Ferroptosis and Oxidative Stress spotlights Z-nucleic acid-binding protein 1 (ZBP1), framing it as an emerging innate immune sensor that links genomic damage to antitumor immunity. The authors argue that deliberately triggering the ZBP1 pathway could convert immunologically “cold” tumors into “hot” ones, potentially reshaping how cancer resistance to immunotherapy is [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365988</post-id>	</item>
		<item>
		<title>New drug candidate offers hope for patients with NRAS-driven melanoma</title>
		<link>https://bioengineer.org/new-drug-candidate-offers-hope-for-patients-with-nras-driven-melanoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 01:54:07 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-drug-candidate-offers-hope-for-patients-with-nras-driven-melanoma/</guid>

					<description><![CDATA[A Huntsman Cancer Institute team at the University of Utah reports that daraxonrasib, a targeted RAS inhibitor, could offer a new treatment route for a subset of melanoma patients whose tumors are driven by NRAS mutations. The work addresses an ongoing clinical gap: effective targeted options for NRAS-mutant metastatic melanoma have been limited, leaving many [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365974</post-id>	</item>
		<item>
		<title>Association for Molecular Pathology Names 2026 Award Winners</title>
		<link>https://bioengineer.org/association-for-molecular-pathology-names-2026-award-winners/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 01:11:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/association-for-molecular-pathology-names-2026-award-winners/</guid>

					<description><![CDATA[ROCKVILLE, Md.—The Association for Molecular Pathology (AMP) has announced the 2026 recipients of its Award for Excellence in Molecular Diagnostics, the Jeffrey A. Kant Leadership Award, and the Meritorious Service Award. Together, the honors recognize scientists and leaders whose work has measurably advanced molecular diagnostics and improved how patients are classified, treated, and monitored. The [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365960</post-id>	</item>
		<item>
		<title>Experimental KRAS Vaccine Stimulates Immune Response in High-Risk Pancreatic Cancer Patients</title>
		<link>https://bioengineer.org/experimental-kras-vaccine-stimulates-immune-response-in-high-risk-pancreatic-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Jul 2026 00:53:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/experimental-kras-vaccine-stimulates-immune-response-in-high-risk-pancreatic-cancer-patients/</guid>

					<description><![CDATA[Researchers at Johns Hopkins Kimmel Cancer Center and the Skip Viragh Center for Pancreatic Cancer report early results from a preventive strategy aimed at mutant KRAS, one of the most common genetic drivers of pancreatic ductal adenocarcinoma. The team describes an experimental peptide vaccine, mKRAS-VAX, designed to train the immune system to recognize and eliminate [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365945</post-id>	</item>
		<item>
		<title>Safe vaccine triggers durable immune responses to prevent pancreatic cancer in high-risk people</title>
		<link>https://bioengineer.org/safe-vaccine-triggers-durable-immune-responses-to-prevent-pancreatic-cancer-in-high-risk-people/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 23:53:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/safe-vaccine-triggers-durable-immune-responses-to-prevent-pancreatic-cancer-in-high-risk-people/</guid>

					<description><![CDATA[A first-in-human study reported that an off-the-shelf vaccine aimed at common mutant KRAS variants can be both safe and immunologically active in people at elevated risk of pancreatic ductal adenocarcinoma (PDAC). The approach targets a core cancer driver present in the vast majority of PDACs, along with many early pancreatic precursors. The work builds on [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365926</post-id>	</item>
		<item>
		<title>Early inflammation signal fuels oral cancer, suggests immunoprevention strategy</title>
		<link>https://bioengineer.org/early-inflammation-signal-fuels-oral-cancer-suggests-immunoprevention-strategy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 22:23:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/early-inflammation-signal-fuels-oral-cancer-suggests-immunoprevention-strategy/</guid>

					<description><![CDATA[Researchers at The University of Texas MD Anderson Cancer Center report an immune pathway that may help oral precancerous lesions progress to head and neck squamous cell carcinoma. The work focuses on early changes in the tumor microenvironment—shifts that can quietly establish immune tolerance long before invasive cancer appears. Published in Cancer Research, the study [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365904</post-id>	</item>
		<item>
		<title>Scientists Discover Immune Cells Form Cancer-Fighting Hubs Within Tumors</title>
		<link>https://bioengineer.org/scientists-discover-immune-cells-form-cancer-fighting-hubs-within-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 21:29:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/scientists-discover-immune-cells-form-cancer-fighting-hubs-within-tumors/</guid>

					<description><![CDATA[Researchers at the Icahn School of Medicine at Mount Sinai report that a rare subset of dendritic cells—specifically dendritic cell type 1—functions as the key architect of tertiary lymphoid structures (TLSs) inside tumors. These immune “outposts” act as on-site command centers where cancer-fighting responses are coordinated locally rather than relying on distant lymph nodes. The [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365881</post-id>	</item>
		<item>
		<title>AirPods-Size Fluorescence Device Could Enable Rapid At-Home Molecular Testing</title>
		<link>https://bioengineer.org/airpods-size-fluorescence-device-could-enable-rapid-at-home-molecular-testing/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 20:29:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/airpods-size-fluorescence-device-could-enable-rapid-at-home-molecular-testing/</guid>

					<description><![CDATA[Researchers at the University of Illinois are tackling a central challenge in home diagnostics: how to replicate laboratory-grade fluorescent molecular testing in a device small enough to live in everyday life. Their work focuses on what a “holistic system” must include—hardware, sensing, workflow design, and user-facing software—to make sensitive pathogen and cancer-associated measurements practical outside [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365867</post-id>	</item>
		<item>
		<title>Black Women’s Breast Cancer Screening Decisions in UK: Qualitative Study</title>
		<link>https://bioengineer.org/black-womens-breast-cancer-screening-decisions-in-uk-qualitative-study/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 18:51:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/black-womens-breast-cancer-screening-decisions-in-uk-qualitative-study/</guid>

					<description><![CDATA[A new qualitative study in the UK is shedding light on a question that sits at the intersection of trust, access, and health equity: why some Black women choose to participate in breast cancer screening while others hesitate—or opt out. Published in British Journal of Cancer on 16 July 2026, the research by Aliu, Kerrison, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365838</post-id>	</item>
		<item>
		<title>Cancer Survivors and Providers Disagree on Medical Cannabis, Study Reveals</title>
		<link>https://bioengineer.org/cancer-survivors-and-providers-disagree-on-medical-cannabis-study-reveals/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 18:39:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cancer-survivors-and-providers-disagree-on-medical-cannabis-study-reveals/</guid>

					<description><![CDATA[Cannabis is increasingly used by cancer survivors to manage pain, nausea, and anxiety, even as evidence on outcomes remains incomplete. Medical cannabis is legal in 47 U.S. states, Washington, D.C., and three territories, and its presence in survivorship care is growing. Yet the field still lacks a clear picture of how patients and clinicians perceive [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365831</post-id>	</item>
		<item>
		<title>Melbourne Consensus Offers Framework and Expert Guidance on Pancreatic Fat Accumulation</title>
		<link>https://bioengineer.org/melbourne-consensus-offers-framework-and-expert-guidance-on-pancreatic-fat-accumulation/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 16:52:01 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/melbourne-consensus-offers-framework-and-expert-guidance-on-pancreatic-fat-accumulation/</guid>

					<description><![CDATA[A new international consensus paper in Nature Reviews Gastroenterology &#038; Hepatology lays out a shared conceptual framework for understanding intrapancreatic fat deposition—fat that accumulates within the pancreas—and offers expert guidance for how clinicians and researchers should study it. Dubbed the “Melbourne consensus,” the work targets a key problem in the field: inconsistent terminology, variable measurement [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365800</post-id>	</item>
		<item>
		<title>Study finds cancer subtype roles in narrowing Black and white mortality gap</title>
		<link>https://bioengineer.org/study-finds-cancer-subtype-roles-in-narrowing-black-and-white-mortality-gap/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 16:46:03 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/study-finds-cancer-subtype-roles-in-narrowing-black-and-white-mortality-gap/</guid>

					<description><![CDATA[Marked reductions in excess mortality for several major cancers signal that population-wide cancer control efforts are making real headway, according to a new cross-sectional temporal analysis. Researchers report that, over time, the gap between observed cancer deaths and expected baseline levels has narrowed for multiple cancer types, reflecting improvements in prevention, early detection, and treatment [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365794</post-id>	</item>
		<item>
		<title>Association for Molecular Pathology Honors Dartmouth Health Director for Long Leadership</title>
		<link>https://bioengineer.org/association-for-molecular-pathology-honors-dartmouth-health-director-for-long-leadership/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 15:49:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/association-for-molecular-pathology-honors-dartmouth-health-director-for-long-leadership/</guid>

					<description><![CDATA[Laura J. Tafe, M.D., a professor of pathology and laboratory medicine at Dartmouth Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth, has been selected for the Association for Molecular Pathology’s (AMP) 2026 Jeffrey A. Kant Leadership Award. The honor recognizes exceptional leadership that advances AMP’s mission in molecular diagnostics. AMP represents professionals [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365772</post-id>	</item>
		<item>
		<title>$2.5M DoD grant supports targeted therapy development for triple-negative breast cancer</title>
		<link>https://bioengineer.org/2-5m-dod-grant-supports-targeted-therapy-development-for-triple-negative-breast-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 16 Jul 2026 14:07:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/2-5m-dod-grant-supports-targeted-therapy-development-for-triple-negative-breast-cancer/</guid>

					<description><![CDATA[Weill Cornell Medicine has secured a $2.5 million, three-year Department of Defense (DoD) Breakthrough Award to create new therapies for triple-negative breast cancer, a subtype widely known for its aggressive behavior and limited treatment options. The program is designed to accelerate innovative approaches with real potential to change patient care. Triple-negative breast cancer is defined [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">365745</post-id>	</item>
	</channel>
</rss>
